Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism

Sci Rep. 2019 Oct 7;9(1):14362. doi: 10.1038/s41598-019-50692-1.

Abstract

Shiga toxin (Stx) is the main virulence factor of enterohemorrhagic Escherichia coli (EHEC), that cause gastrointestinal infection leading to hemolytic uremic syndrome. The aim of this study was to investigate if Stx signals via ATP and if blockade of purinergic receptors could be protective. Stx induced ATP release from HeLa cells and in a mouse model. Toxin induced rapid calcium influx into HeLa cells, as well as platelets, and a P2X1 receptor antagonist, NF449, abolished this effect. Likewise, the P2X antagonist suramin blocked calcium influx in Hela cells. NF449 did not affect toxin intracellular retrograde transport, however, cells pre-treated with NF449 exhibited significantly higher viability after exposure to Stx for 24 hours, compared to untreated cells. NF449 protected HeLa cells from protein synthesis inhibition and from Stx-induced apoptosis, assayed by caspase 3/7 activity. The latter effect was confirmed by P2X1 receptor silencing. Stx induced the release of toxin-positive HeLa cell- and platelet-derived microvesicles, detected by flow cytometry, an effect significantly reduced by NF449 or suramin. Suramin decreased microvesicle levels in mice injected with Stx or inoculated with Stx-producing EHEC. Taken together, we describe a novel mechanism of Stx-mediated cellular injury associated with ATP signaling and inhibited by P2X receptor blockade.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Benzenesulfonates / pharmacology
  • Blood Platelets / microbiology
  • Enterohemorrhagic Escherichia coli / drug effects
  • Enterohemorrhagic Escherichia coli / pathogenicity
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / genetics
  • Escherichia coli Infections / microbiology
  • Escherichia coli Infections / pathology
  • HeLa Cells
  • Hemolytic-Uremic Syndrome / drug therapy*
  • Hemolytic-Uremic Syndrome / genetics
  • Hemolytic-Uremic Syndrome / microbiology
  • Hemolytic-Uremic Syndrome / pathology
  • Humans
  • Mice
  • Purinergic P2X Receptor Antagonists / pharmacology
  • Receptors, Purinergic P2X1 / genetics*
  • Shiga Toxin / antagonists & inhibitors
  • Shiga Toxin / genetics*

Substances

  • 4,4,',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis(benzene-1,3-disulfonate)
  • Benzenesulfonates
  • Purinergic P2X Receptor Antagonists
  • Receptors, Purinergic P2X1
  • Shiga Toxin
  • Adenosine Triphosphate